Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Nov 2015
At a glance
- Drugs Melatonin (Primary) ; Olanzapine (Primary)
- Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 20 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 20 Nov 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 18 Dec 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.